We are improving the lives of people suffering from mental illness and substance use disorders
What we do
HQ & Pipeline
Digital Therapeutics
Discover our story
Key News
SEPTEMBER 9, 2022
Orexo´s partner announces the result from the phase 2 study for OXMPI
SEPTEMBER 7, 2022
Trinity Health announces the availability of vorvida® and deprexis® to patients
SEPTEMBER 1, 2022
First patent issued for Orexo´s adrenaline product in Europe
Listed on Nasdaq Stockholm´s mainlist
Orexo is listed on Nasdaq Stockholm´s mainlist, Mid Cap, (ORX), and can be traded in the US at the OTCQX Market (ORXOY).
MODIA® - our digital therapy for opioid dependence
- to be used along with pharmaceuticals
- 6 months treatment
- grounded in cognitive behavioral therapy techniques
- available 24/7
- ongoing clinical trial incl. up to 400 patients
News Flow
Press Releases & News
Orexo’s partner Gesynta Pharma has announced phase II study results from the OX-MPI (GS-248) project
Orexo’s partner Trinity Health today announces the availability of vorvida® and deprexis® to patients
First patent issued in Europe for Orexo’s adrenaline product OX640
Orexo to participate in Pareto Securities´ 13th Annual Healthcare Conference
Orexo Social
@OrexoABpubl
23 September 2022
#Orexo looks forward to being part of the US Pavillion exhibition at NLS Days, Sep. 28-29. Along with our co-hosts,… https://t.co/NhMbJkltuo
@OrexoABpubl
19 September 2022
Klas Palin analytiker på Erik Penser Bank intervjuar Orexos VD om den senaste utvecklingen inom digitala behandlina… https://t.co/KVwvbximNk
@OrexoABpubl
16 September 2022
In 2013 #Orexo launched its lead product for opioid dependence on the US market. Since then, total net sales have r… https://t.co/aScs7f0yaw
Financial Snapshot
Group net revenues
597 MSEK
LTM1
Group EBITDA
-126 MSEK
LTM1
US Pharma segment EBIT
312 MSEK
LTM1
Cash position
468 MSEK
Q2 2022
1 Last Twelve Months, Q321-Q222, for more information about financial development Link